TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Glutamine is the most abundant nonessential amino acid in the human body. Besides its role as a constituent of proteins and its importance in amino acid transamination, glutamine may modulate immune cells.

The innate immune system is the first line of host defence against pathogens and in most cases sufficient to eliminate invading microbes. Mammalian Toll-like receptors (TLR) comprise a family of germ line-encoded trans-membrane receptors which activation leads to the induction of inflammatory responses, phagocytosis but also to the development of antigen specific adapative immunity.

It has been postulated though not formally proven yet that glutamine beneficial effect could be due to a positive effect on the innate immune system. Given the importance of TLRs and TLRs-dependent signalling in host defence against infections we hypothesized that glutamine may increase the expression and/or functionality of TLRs which in turn may have beneficial effects to clear infections.


Options:
A: Arm Label: Enteral Glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Enteral Glutamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Enteral Glutamine; Assigned to Arm(s): Enteral Glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Other: Glutamine | Arm Label: Antioxidants; Type: EXPERIMENTAL; Interventions: Other: Antioxidants | Arm Label: Glutamine + Antioxidants; Type: EXPERIMENTAL; Interventions: Other: Glutamine + Antioxidants | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: OTHER; Name: Antioxidants; Assigned to Arm(s): Antioxidants | Intervention Type: OTHER; Name: Glutamine + Antioxidants; Assigned to Arm(s): Glutamine + Antioxidants | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Total Parenteral Nutrition with Glutamine | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Total Parenteral Nutrition without glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: Total Parenteral Nutrition with Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: OTHER; Name: Total Parenteral Nutrition without glutamine; Assigned to Arm(s): Control
D: Arm Label: alanyl-glutamine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dipeptiven | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: normal saline | Intervention Type: DIETARY_SUPPLEMENT; Name: Dipeptiven; Assigned to Arm(s): alanyl-glutamine | Intervention Type: DIETARY_SUPPLEMENT; Name: normal saline; Assigned to Arm(s): normal saline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment
Brief Summary: This randomized, open-label, parallel-group study will assess the efficacy and s afety of Avastin (bevacizumab) in combination with chemotherapy versus chemother apy alone as second- and third-line therapy in patients with locally recurrent o r metastatic breast cancer progressing after first-line therapy with Avastin and chemotherapy. Patients will be randomized to receive either Avastin (15 mg/kg e very 3 weeks or 10 mg/kg every 2 weeks intravenously) plus standard chemotherapy or chemotherapy alone. Anticipated time on study treatment is until third-line disease progression or unacceptable toxicity occurs.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin], Drug: Chemotherapy | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): 1, 2
B: Intervention Type: BIOLOGICAL; Name: trastuzumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
C: Arm Label: resp: 4xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: resp: 6xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: nonResp: 4xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: nonResp: 4xNX; Type: EXPERIMENTAL; Interventions: Drug: NX | Intervention Type: DRUG; Name: TAC; Assigned to Arm(s): nonResp: 4xTAC, resp: 4xTAC, resp: 6xTAC | Intervention Type: DRUG; Name: NX; Assigned to Arm(s): nonResp: 4xNX
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E7389 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's Choice | Intervention Type: DRUG; Name: E7389; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Physician's Choice; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Asthma Outcomes Through Cultural Competence Training for Physicians
Brief Summary: The proposed randomized clinical trial will compare two educational interventions: Physicians Asthma Care Education (PACE) and PACE Plus with 90 physicians in Atlanta and the Bronx and their 1192 patients.


Options:
A: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone counseling intervention | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telephone counseling intervention; Assigned to Arm(s): Intervention
C: Arm Label: PACE Plus; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PACE Plus | Arm Label: PACE; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PACE | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PACE; Assigned to Arm(s): PACE | Intervention Type: BEHAVIORAL; Name: PACE Plus; Assigned to Arm(s): PACE Plus
D: Arm Label: Group 2: community video group; Type: EXPERIMENTAL; Interventions: Behavioral: patient role played community video, Behavioral: Community video group | Arm Label: Group three: both videos group; Type: EXPERIMENTAL; Interventions: Behavioral: both videos group | Arm Label: Group four: pamphlet group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pamphlet group | Arm Label: Group one: knowledge video group; Type: EXPERIMENTAL; Interventions: Behavioral: physician-led knowledge video, Behavioral: knowledge video | Intervention Type: BEHAVIORAL; Name: patient role played community video; Assigned to Arm(s): Group 2: community video group | Intervention Type: BEHAVIORAL; Name: both videos group; Assigned to Arm(s): Group three: both videos group | Intervention Type: BEHAVIORAL; Name: Pamphlet group; Assigned to Arm(s): Group four: pamphlet group | Intervention Type: BEHAVIORAL; Name: physician-led knowledge video; Assigned to Arm(s): Group one: knowledge video group | Intervention Type: BEHAVIORAL; Name: Community video group; Assigned to Arm(s): Group 2: community video group | Intervention Type: BEHAVIORAL; Name: knowledge video; Assigned to Arm(s): Group one: knowledge video group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of Three Successive Periods of 3-month Open-label PGL4001 Treatment, Each Followed by Ten Days of Double-blind Treatment With Progestin or Placebo and a Drug-free Period Until Return of Menses, in Subjects With Myomas and Heavy Uterine Bleeding
Brief Summary: This is the long-term extension of a phase III, efficacy and safety open-label (protocol PGL09-026) with PGL4001 10mg tablets once daily for three months, blinded towards the administration of progestin or placebo tablets after end of PGL4001 treatment.

This extension study consists of three periods of 3 months open-label PGL4001 treatment, each followed by ten days of double-blind treatment with progestin or placebo and then a period without treatment.


Options:
A: Arm Label: ulipristal acetate -20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 20 mg | Arm Label: ulipristal acetate - 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pre-ulipristal acetate 10 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-ulipristal acetate 20 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ulipristal acetate 20 mg; Assigned to Arm(s): ulipristal acetate -20 mg | Intervention Type: DRUG; Name: ulipristal acetate 10 mg; Assigned to Arm(s): ulipristal acetate - 10 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mifegyne | Intervention Type: DRUG; Name: Mifegyne; Assigned to Arm(s): I | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin | Intervention Type: DRUG; Name: PGL4001, placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin; Assigned to Arm(s): B
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo, drug free period | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin, drug free period | Intervention Type: DRUG; Name: PGL4001, placebo, drug free period; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin, drug free period; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of Three Successive Periods of 3-month Open-label PGL4001 Treatment, Each Followed by Ten Days of Double-blind Treatment With Progestin or Placebo and a Drug-free Period Until Return of Menses, in Subjects With Myomas and Heavy Uterine Bleeding
Brief Summary: This is the long-term extension of a phase III, efficacy and safety open-label (protocol PGL09-026) with PGL4001 10mg tablets once daily for three months, blinded towards the administration of progestin or placebo tablets after end of PGL4001 treatment.

This extension study consists of three periods of 3 months open-label PGL4001 treatment, each followed by ten days of double-blind treatment with progestin or placebo and then a period without treatment.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo, drug free period | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin, drug free period | Intervention Type: DRUG; Name: PGL4001, placebo, drug free period; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin, drug free period; Assigned to Arm(s): B
B: Arm Label: Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: Inert capsule; Type: PLACEBO_COMPARATOR; Interventions: Drug: Inert Capsule | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Mifepristone | Intervention Type: DRUG; Name: Inert Capsule; Assigned to Arm(s): Inert capsule
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Ulipristal acetate (PGL4001) 5mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 5 mg | Arm Label: Ulipristal acetate (PGL4001) 10mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 10 mg | Intervention Type: DRUG; Name: PGL4001 5 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 5mg | Intervention Type: DRUG; Name: PGL4001 10 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 10mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (cαStx1) and 2 (cαStx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial)
Brief Summary: This study is designed to evaluate the safety and efficacy of cαStx1 and cαStx2 administered concomitantly in children presenting early signs of Shiga Toxin-Producing Bacterial (STPB) Infection.


Options:
A: Arm Label: SYNSORB Pk; Type: EXPERIMENTAL; Interventions: Drug: SYNSORB Pk | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SYNSORB Pk; Assigned to Arm(s): SYNSORB Pk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: cαStx1/cαStx2; Type: EXPERIMENTAL; Interventions: Drug: cαStx1/cαStx2 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: cαStx1/cαStx2; Assigned to Arm(s): cαStx1/cαStx2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: Admission/Intravascular Volume Expansion; Type: EXPERIMENTAL; Interventions: Drug: D5-0.9%NS | Arm Label: Outpatient Observation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Routine home oral rehydration | Intervention Type: DRUG; Name: D5-0.9%NS; Assigned to Arm(s): Admission/Intravascular Volume Expansion | Intervention Type: DRUG; Name: Routine home oral rehydration; Assigned to Arm(s): Outpatient Observation
D: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Children's Intake of Foods Reduced in Energy Density
Brief Summary: The purpose of this research is to investigate children's responses to incorporating vegetables into selected entrees and snacks over several days. The hypothesis is that children will increase their vegetable intake by consuming foods that have been reduced in energy density through the addition of vegetables. Effects on energy intake will also be examined.


Options:
A: Arm Label: Entree energy density 100%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 85%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 75%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Intervention Type: OTHER; Name: Energy density feeding study; Assigned to Arm(s): Entree energy density 100%, Entree energy density 75%, Entree energy density 85%
B: Arm Label: 100% Portion Size; Type: EXPERIMENTAL; Interventions: Other: Food and Beverage Portion Size | Arm Label: 150% Portion Size; Type: EXPERIMENTAL; Interventions: Other: Food and Beverage Portion Size | Intervention Type: OTHER; Name: Food and Beverage Portion Size; Assigned to Arm(s): 100% Portion Size, 150% Portion Size
C: Arm Label: Vegetable exposure; Type: EXPERIMENTAL; Interventions: Other: Vegetable exposure | Arm Label: VIPP-Feeding Infants; Type: EXPERIMENTAL; Interventions: Behavioral: VIPP-Feeding Infants | Arm Label: Exposure + VIPP-FI; Type: EXPERIMENTAL; Interventions: Other: Vegetable exposure, Behavioral: VIPP-Feeding Infants | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Vegetable exposure; Assigned to Arm(s): Exposure + VIPP-FI, Vegetable exposure | Intervention Type: BEHAVIORAL; Name: VIPP-Feeding Infants; Assigned to Arm(s): Exposure + VIPP-FI, VIPP-Feeding Infants | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Intervention Type: BEHAVIORAL; Name: Promotion of a healthy diet and physical activity; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Avoidance of Alcohol, Drugs, and Tobacco; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Children's Intake of Foods Reduced in Energy Density
Brief Summary: The purpose of this research is to investigate children's responses to incorporating vegetables into selected entrees and snacks over several days. The hypothesis is that children will increase their vegetable intake by consuming foods that have been reduced in energy density through the addition of vegetables. Effects on energy intake will also be examined.


Options:
A: Arm Label: Cucumber; Type: EXPERIMENTAL; Interventions: Other: Cucumber snack | Arm Label: Pepper; Type: EXPERIMENTAL; Interventions: Other: Pepper snack | Arm Label: Tomato; Type: EXPERIMENTAL; Interventions: Other: Tomato snack | Arm Label: Vegetable variety; Type: EXPERIMENTAL; Interventions: Other: Vegetable variety snack | Arm Label: Apple; Type: EXPERIMENTAL; Interventions: Other: Apple snack | Arm Label: Peach; Type: EXPERIMENTAL; Interventions: Other: Peach snack | Arm Label: Pineapple; Type: EXPERIMENTAL; Interventions: Other: Pineapple snack | Arm Label: Fruit variety; Type: EXPERIMENTAL; Interventions: Other: Fruit variety snack | Intervention Type: OTHER; Name: Cucumber snack; Assigned to Arm(s): Cucumber | Intervention Type: OTHER; Name: Pepper snack; Assigned to Arm(s): Pepper | Intervention Type: OTHER; Name: Tomato snack; Assigned to Arm(s): Tomato | Intervention Type: OTHER; Name: Vegetable variety snack; Assigned to Arm(s): Vegetable variety | Intervention Type: OTHER; Name: Apple snack; Assigned to Arm(s): Apple | Intervention Type: OTHER; Name: Peach snack; Assigned to Arm(s): Peach | Intervention Type: OTHER; Name: Pineapple snack; Assigned to Arm(s): Pineapple | Intervention Type: OTHER; Name: Fruit variety snack; Assigned to Arm(s): Fruit variety
B: Arm Label: Entree energy density 100%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 85%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 75%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Intervention Type: OTHER; Name: Energy density feeding study; Assigned to Arm(s): Entree energy density 100%, Entree energy density 75%, Entree energy density 85%
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Wait-listed control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): intervention
D: Intervention Type: BEHAVIORAL; Name: attitude change; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: adiposity prevention program; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Children's Intake of Foods Reduced in Energy Density
Brief Summary: The purpose of this research is to investigate children's responses to incorporating vegetables into selected entrees and snacks over several days. The hypothesis is that children will increase their vegetable intake by consuming foods that have been reduced in energy density through the addition of vegetables. Effects on energy intake will also be examined.


Options:
A: Arm Label: Enhanced Go NAPSACC; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Go NAPSACC | Arm Label: Basic Go NAPSACC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Go NAPSACC | Intervention Type: BEHAVIORAL; Name: Enhanced Go NAPSACC; Assigned to Arm(s): Enhanced Go NAPSACC | Intervention Type: BEHAVIORAL; Name: Basic Go NAPSACC; Assigned to Arm(s): Basic Go NAPSACC
B: Arm Label: Healthy Lifestyles Group; Type: EXPERIMENTAL; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Arm Label: Healthy Business Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Intervention Type: BEHAVIORAL; Name: Keys to Healthy Family Child Care Homes; Assigned to Arm(s): Healthy Business Group, Healthy Lifestyles Group
C: Arm Label: Entree energy density 100%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 85%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 75%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Intervention Type: OTHER; Name: Energy density feeding study; Assigned to Arm(s): Entree energy density 100%, Entree energy density 75%, Entree energy density 85%
D: Arm Label: Survey; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Children's Intake of Foods Reduced in Energy Density
Brief Summary: The purpose of this research is to investigate children's responses to incorporating vegetables into selected entrees and snacks over several days. The hypothesis is that children will increase their vegetable intake by consuming foods that have been reduced in energy density through the addition of vegetables. Effects on energy intake will also be examined.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling
B: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
C: Arm Label: Lunch in the Bag Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lunch is in the Bag behavioral intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lunch is in the Bag behavioral intervention; Assigned to Arm(s): Lunch in the Bag Intervention
D: Arm Label: Entree energy density 100%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 85%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 75%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Intervention Type: OTHER; Name: Energy density feeding study; Assigned to Arm(s): Entree energy density 100%, Entree energy density 75%, Entree energy density 85%

Answer: D